Aura Biosciences Inc. (AURA), a clinical-stage biotechnology company, announced on Monday the pricing of its underwritten public offering of 39.59 million shares of common stock at $6 per share.
Following the announcement, shares reached a 52-week high at $8.49.
To certain investors, the company is also offering pre-funded warrants of 3.8 million shares at $5.99999 per pre-funded warrant, at an exercise rate of $0.00001.
The offer is expected to close on May 5, 2026.
The company is also granting underwriters a 30-day option to purchase an additional 6.51 million shares at the offering price.
The gross proceeds from the offering are estimated to be $260.30 million, and the company plans to utilize $205.10 million to advance clinical programs in early choroidal melanoma, in registration-enabling activities for lead drug candidate bel--sar, and for general corporate purposes.
The remaining amount from the proceeds will be used to repurchase 6,922,870 shares from the Matrix Capital Management Fund, currently held at $5.64 per share.
AURA closed Monday at $8.35, up 19.12%. In after-hours, shares were trading at $8.40, up 0.60%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.